rhNRG1 treatment induced systemic activation of ErbB2 and ErbB4 receptors in both heart and kidneys and prevented left ventricular dilatation, improved left ventricular contractile function, and reduced atherosclerotic plaque size. (Vandekerckhove et al., 2016). This evidence concerns the gene ERBB2 and Left ventricular dilatation.